Abstract
Immunotherapy with Sizofilan has been used for treating oral cancers in our department since 1987. Eight cases were observed in this study. Immunological investigations revealed the following findings: 1) Lymphocytes decreased after operation plus radioand chemotherapy, but the return to the pretreatment level could been achieved 2-3 months after operation. 2) The values of OKT 3 and 4 well corresponded to the lymphocyte count at each stage. 3) The values of OKT 8 indicated low level in controlled cases, on the other side comparatively high level in un-controlled cases at each stage. For the reasons stated abve, Sizofilan contributes to promote active immunological mechanisms of patients concerning therapeutic procedure against cancer.
